Abstract The World Health Organization classification of lymphoid neoplasms updated in
2008 represents a worldwide consensus on the diagnosis of these tumors and is based on …

Genomic analysis has greatly influenced the diagnosis and clinical management of patients
affected by diverse forms of hematologic malignancies. Here, we review how genetic …

Purpose Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and
the existence of a subgroup with poor prognosis and phenotypic proximity to Burkitt …

Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC …

Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

Purpose Approximately 5% of diffuse large B-cell lymphomas (DLBCLs) are double-hit
lymphomas (DHLs) with translocations of both MYC and BCL2. DHLs are characterized by …

MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and
confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell non-Hodgkin lymphoma that
affects patients of all ages with a wide range of clinical presentations. Although DLBCL is …

We report our experience with 129 cases of double hit lymphoma (DHL), defined as B‐cell
lymphoma with translocations and/or extra signals involving MYC plus BCL 2 and/or BCL 6 …

Lastly, this edition deserves special attention due to its emphasis on LP related to pathogens
and/or arising in the context of acquired immune suppression. Following, we will briefly …